Full Press Release Details
argenx announces closing of U.S. public offering for gross proceeds of approximately $266 million.
ARGX
argenx announces closing of U.S. public offering for gross proceeds of approximately $266 million
Key Takeaway: argenx announces closing of U.S. public offering for gross proceeds of approximately $266 million
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+42%
120-day peak, hindsight
Typical move
4%
average across 14 past catalysts
Lead asset
Empasiprubart
Phase 2 · Dermatomyositis